Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT03677141
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
- NCT03677141 ↗
- Completed
- Hoffmann-La Roche
- Focused
We haven't built an HCP commentary report on NCT03677141 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03677141 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Status
- Completed
- Conditions
- B-cell Non-Hodgkin Lymphoma
- Interventions
- Mosunetuzumab; Polatuzumab Vedotin; Rituxumab; Cyclophosphamide; Doxorubicin; Vincristine; Prednisone; Tocilizumab
- Arms
- Phase Ib: Mosunetuzumab (M)-CHOP Dose Finding · Experimental
- Phase Ib: M-CHP-Pola Dose-Finding · Experimental
- Phase II: M-CHOP Previously Untreated (1L) DLBCL Safety Cohort · Experimental
- Phase II: M-CHP-Pola 1L DLBCL · Experimental
- Phase II: Rituxumab (R)-CHP-Pola 1L DLBCL · Active comparator
- Phase II: M-CHOP 1L DLBCL · Experimental
- Enrollment
- 117
- Primary outcomes
- Complete Response (CR) Rate at the Time of Primary Response Assessment (PRA) Based on Positron Emission Tomography - Computed Tomography (PET-CT) as Determined by Independent Review Committee (IRC)
- Sponsor
- Hoffmann-La Roche
- Start
- Mar 8, 2019
- Primary completion
- Oct 12, 2023
- Results posted
- Yes
- Registry record
- NCT03677141 · updated Dec 18, 2024
Publications
linked from the registry- Westin J, Phillips TJ, Mehta A, Hoffmann MS, Gonzalez-Barca E, Thieblemont C, Bastos-Oreiro M, Greil R, Giebel S, Wei MC, Wang J, Bucher R, Sit J, Penuel E, Purev E, Yee DL, Bergua-Burgues JM. Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a phase 2 study. Blood Adv. 2025 May 27;9(10):2461-2472. doi: 10.1182/bloodadvances.2024014907. PubMed 39908481
- Olszewski AJ, Phillips TJ, Hoffmann MS, Armand P, Kim TM, Yoon DH, Mehta A, Greil R, Westin J, Lossos IS, Munoz JL, Sit J, Wei MC, Yang A, Chen V, Purev E, Yee DL, Jaeger U. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study. Blood Adv. 2023 Oct 24;7(20):6055-6065. doi: 10.1182/bloodadvances.2023010840. PubMed 37581593